Navigation Links
NeuroPhage to Participate in World's First G8 Dementia Summit
Date:12/3/2013

CAMBRIDGE, Mass., Dec. 3, 2013 /PRNewswire/ -- NeuroPhage Pharmaceuticals, Inc. today announced that it has been invited to participate in the world's first G8 Dementia Summit. The G8 Summit is hosted by the British Prime Minister, David Cameron, and Health Secretary, Jeremy Hunt, and will be attended by G8 Health Ministers, pharmaceutical company leaders, innovators, technology pioneers, breakthrough researchers and investors. The Summit will explore the coordination of efforts to shape an effective international solution to dementia, a condition that affects over 35 million people worldwide, including looking for effective therapies to slow dementia's impact. The G8 Dementia Summit will take place in London, UK, on December 11, 2013.

"We applaud this groundbreaking initiative that the Prime Minister and the Health Secretary have undertaken to bring together leaders from government, research and finance to focus on addressing the enormous health and economic burden that dementia has on patients and families around the world," said Jonathan Solomon, President and Chief Executive Officer of NeuroPhage. "Dementia has proved to be a challenging indication to treat, as the biology behind the various conditions is complex. We are honored to take part in this ambitious international effort in hopes to create a greater collaborative approach worldwide to better achieve our common goals of treating and preventing dementia."

About NeuroPhage  

NeuroPhage Pharmaceuticals has fusion-protein drug candidates in development for neurodegenerative diseases, many of which cause progressive mental deterioration and dementia.  NeuroPhage's technology is based on a General Amyloid Interaction Motif (GAIM) that simultaneously targets multiple misfolded proteins or amyloids central to many neurodegenerative
'/>"/>

SOURCE NeuroPhage Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. NeuroPhage, Inc. Raises $6.4 Million In Additional Financing
2. Uroplasty To Participate In The Piper Jaffray Healthcare Conference
3. Hill-Rom to Participate in the 25th Annual Piper Jaffray Healthcare Conference
4. ProVen Pharmaceuticals Participates in the Dolphins Cycling Challenge
5. Boston Scientific To Participate In 2013 Credit Suisse Healthcare Conference
6. Inovio Pharmaceuticals to Participate in Immunotherapy Panel and Present at the 12th Annual BIO Investor Forum
7. Uroplasty To Participate In The Craig-Hallum Alpha Select Conference
8. montmed to participate in Vascular 2013
9. Questcor Pharmaceuticals to Participate in Morgan Stanley Global Healthcare Conference
10. Amgen To Participate At Citis 8th Annual Biotech Conference
11. China Biologic to Participate in Upcoming Investor Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/22/2014)... ALTO, Calif. , Dec, 22, 2014 /PRNewswire/ ... a Phase 2a study of lonafarnib in patients ... study was conducted at the National Institutes of ... Maryland .  The double-blinded, randomized, placebo-controlled, dose ... mg twice daily and 200 mg twice daily ...
(Date:12/22/2014)... 2014  Relmada Therapeutics, Inc. (OTCQB: RLMD), a ... of chronic pain, announced today that the first ... pharmacokinetic and pharmacodynamic study with d-Methadone, the company,s ... Racemic methadone is a long-acting opioid used ... substitution therapy in opioid addiction.  It is constituted ...
(Date:12/19/2014)... Friday, December 19 edition of USA ... features Konica Minolta, the company announced today. The supplement will focus ... organizations. In addition to the print section that ... New York , Chicago , ... Minneapolis and San Francisco , a ...
Breaking Medicine Technology:Eiger Bio Announces Positive Data in Patients Infected with Hepatitis Delta Virus (HDV) Treated with Lonafarnib - Results Presented at American Association for the Study of Liver Diseases (AASLD) Meeting 2Eiger Bio Announces Positive Data in Patients Infected with Hepatitis Delta Virus (HDV) Treated with Lonafarnib - Results Presented at American Association for the Study of Liver Diseases (AASLD) Meeting 3Relmada Therapeutics Doses First Cohort of Subjects in Human Clinical Trial of d-Methadone 2Relmada Therapeutics Doses First Cohort of Subjects in Human Clinical Trial of d-Methadone 3USA Today Supplement Featuring Konica Minolta Focuses on Impact of Healthcare IT 2
... Texas , May 5 HealthTronics, Inc. (Nasdaq: ... services, today announced that it has signed a definitive merger ... which Endo will acquire HealthTronics.  Under the terms of the ... to acquire all of the outstanding shares of HealthTronics common ...
... Watson Pharmaceuticals, Inc. (NYSE: WPI ... filed an Abbreviated New Drug Application (ANDA) with the ... market a raloxifene hydrochloride tablet.  Watson,s raloxifene hydrochloride tablet ... ® is indicated for the treatment and prevention of ...
Cached Medicine Technology:HealthTronics Enters Into Definitive Merger Agreement With Endo Pharmaceuticals 2HealthTronics Enters Into Definitive Merger Agreement With Endo Pharmaceuticals 3HealthTronics Enters Into Definitive Merger Agreement With Endo Pharmaceuticals 4HealthTronics Enters Into Definitive Merger Agreement With Endo Pharmaceuticals 5HealthTronics Enters Into Definitive Merger Agreement With Endo Pharmaceuticals 6HealthTronics Enters Into Definitive Merger Agreement With Endo Pharmaceuticals 7Watson Confirms EVISTA(R) Patent Challenge 2Watson Confirms EVISTA(R) Patent Challenge 3
(Date:12/22/2014)... CA (PRWEB) December 22, 2014 ... now offering consultations for sleep apnea. Drowsy drivers are ... than drivers who are well-rested, and some experts believe ... the roads as intoxicated drivers. Unfortunately, millions of Americans ... the American Academy of Sleep Medicine, about 18 million ...
(Date:12/22/2014)... Luxury Linen purveyor Peacock Alley ... to provide logistics and support for one of Dallas’ ... a long history of giving back to the community in ... year's Toy Drive were Whataburger® and 99.5 The Wolf. , ... holidays. Providing gifts to children who would otherwise not receive ...
(Date:12/22/2014)... 21, 2014 A substantial percentage ... computed tomography (CT) to evaluate abnormal findings on ... cancer, according to a new study published online ... the findings show that radiologist recommendations for additional ... to patient care. , RAIs, which have grown ...
(Date:12/21/2014)... (PRWEB) December 22, 2014 In ... is segmented by power source, product, and application. ... electric-powered, battery-powered, and pneumatic instruments. By product, the ... and accessories segments. The handpieces market is further ... devices, suction coagulators, laparoscopic instruments, shavers, wire/pin drivers, ...
(Date:12/21/2014)... 2014 Khanna Vision Institute is pleased ... the Aspen Helicopters holiday event for underprivileged kids. The ... sleigh, flown by an aspen helicopter pilot. In the ... with sleigh was visible.(please see accompanying video). Helicopter pilots ... has helped many pilots with Pi in eye vision ...
Breaking Medicine News(10 mins):Health News:Pasadena Dentist, Dr. Marine Martirosyan, Now Offers Consultations for Sleep Apnea 2Health News:Peacock Alley and Community Partners of Dallas Fulfill an Estimated 12,000 Holiday Wishes for Deserving Children 2Health News:RSNA: Radiologist Recommendations for Chest CT Have High Clinical Yield 2Health News:RSNA: Radiologist Recommendations for Chest CT Have High Clinical Yield 3Health News:Global Powered Surgical Instruments Market Hit to $2.1 billion by 2019 - New Research Report by MarketsandMarkets 2Health News:Global Powered Surgical Instruments Market Hit to $2.1 billion by 2019 - New Research Report by MarketsandMarkets 3Health News:Global Powered Surgical Instruments Market Hit to $2.1 billion by 2019 - New Research Report by MarketsandMarkets 4
... chromosomes can break and reshuffle pieces of themselves is nothing ... cells. The rules for where chromosomes are likely to break ... now starting to come into view. Researchers at Children,s Hospital ... those rules into clearer focus by discovering that where each ...
... PHILADELPHIA -- In an effort to reduce and eventually eliminate ... Kimmel Cancer Center at Jefferson has established the ... P. Mitchell, M.D., FACP , a medical oncologist at ... and Medical Oncology in the Department of Medical Oncology at ...
... 16 (HealthDay News) -- About 7.5 million American children under ... with alcohol abuse over the past year, a new government ... across the country, say researchers at the Substance Abuse and ... "The enormity of this public health problem goes well ...
... Feb. 16 (HealthDay News) -- Researchers have sequenced the genomes ... transmissible facial cancer that threatens the species with extinction. ... found only on the Australian island of Tasmania, according to ... Cell . "There are targeted drugs that work ...
... painACTION.com is a free, non-promotional online program designed ... people with chronic pain. This study tested painACTION.com,s ... in people with chronic migraine headaches. A total ... to painACTION.com were more confident that they could ...
... JOLLA,CA -- Drugs targeting an enzyme involved in inflammation might ... to a new study by scientists at the Salk Institute ... activity of the enzyme IKK2, which helps activate the body,s ... lung cancer and increased their lifespan. The findings, ...
Cached Medicine News:Health News:To understand chromosome reshuffling, look to the genome's 3D structure 2Health News:To understand chromosome reshuffling, look to the genome's 3D structure 3Health News:To understand chromosome reshuffling, look to the genome's 3D structure 4Health News:Jefferson's Kimmel Cancer Center establishes Center to Eliminate Cancer Disparities 2Health News:Jefferson's Kimmel Cancer Center establishes Center to Eliminate Cancer Disparities 3Health News:Genome Map Might Help Save Tasmanian Devil From Extinction 2Health News:painACTION.com improves migraine self-management and reduces migraine-related psychological distress 2Health News:Salk researchers find new drug target for lung cancer 2Health News:Salk researchers find new drug target for lung cancer 3
... high-power, long-pulse Nd:YAG technology provides practitioners with the ... lesions and perform permanent hair reduction on all ... size feature allows the practitioner to instantly switch ... spot size with a simple twist of the ...
...
...
... is your system. CONMED's family of products ... New, state-of-the art generators feature proprietary Energy ... continuous synchronization of current and voltage in ... enables the system to sample current and ...
Medicine Products: